NIH corrals biopharma companies, regulators and trial networks to coordinate Covid-19 R&D
Francis Collins’ grand plan to bring order to the chaotic rush for Covid-19 vaccines and treatments is here.
The public-private partnership that the NIH director teased a few days ago will be known as ACTIV or Accelerating COVID-19 Therapeutic Interventions and Vaccines. By compiling resources, leveraging existing networks, lobbying regulators and setting up a steering committee to prioritize promising candidates, the goal is to generate more comprehensive data quicker.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.